Literature DB >> 18654701

Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations.

Katerina Capková1, Mark S Hixon, Laura A McAllister, Kim D Janda.   

Abstract

The development of a sensitive, yet reliable assay for the analysis of botulinum neurotoxin A (BoNT/A) inhibitors is described; using this assay a new protease inhibitor was characterized and found to be one of the most potent inhibitors reported to date.

Mesh：

Substances：

Year:  2008        PMID： 18654701     DOI： 10.1039/b808305c

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  22 in total

1.  Synthesis and evaluation of library of betulin derivatives against the botulinum neurotoxin A protease.

Authors:  Peter Šilhár; Sami Alakurtti; Kateřina Čapková; Feng Xiaochuan; Charles B Shoemaker; Jari Yli-Kauhaluoma; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2011-03-04       Impact factor: 2.823

2.  Targeting botulinum A cellular toxicity: a prodrug approach.

Authors:  Peter Silhár; Lisa M Eubanks; Hajime Seki; Sabine Pellett; Sacha Javor; William H Tepp; Eric A Johnson; Kim D Janda
Journal:  J Med Chem       Date:  2013-10-15       Impact factor: 7.446

Review 3.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

4.  Benzoquinones as inhibitors of botulinum neurotoxin serotype A.

Authors:  Paul T Bremer; Mark S Hixon; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2014-06-16       Impact factor: 3.641

5.  A high-throughput-compatible FRET-based platform for identification and characterization of botulinum neurotoxin light chain modulators.

Authors:  Dejan Caglič; Kristin M Bompiani; Michelle C Krutein; Petr Čapek; Tobin J Dickerson
Journal:  J Vis Exp       Date:  2013-12-27       Impact factor: 1.355

6.  A cross-over inhibitor of the botulinum neurotoxin light chain B: a natural product implicating an exosite mechanism of action.

Authors:  Nicholas T Salzameda; Lisa M Eubanks; Joseph S Zakhari; Kyoji Tsuchikama; Nicholas J DeNunzio; Karen N Allen; Mark S Hixon; Kim D Janda
Journal:  Chem Commun (Camb)       Date:  2011-01-04       Impact factor: 6.222

7.  Catch and Anchor Approach To Combat Both Toxicity and Longevity of Botulinum Toxin A.

Authors:  Lucy Lin; Margaret E Olson; Takashi Sugane; Lewis D Turner; Margarita A Tararina; Alexander L Nielsen; Elbek K Kurbanov; Sabine Pellett; Eric A Johnson; Seth M Cohen; Karen N Allen; Kim D Janda
Journal:  J Med Chem       Date:  2020-09-18       Impact factor: 7.446

8.  Effects of hydroxamate metalloendoprotease inhibitors on botulinum neurotoxin A poisoned mouse neuromuscular junctions.

Authors:  Baskaran Thyagarajan; Joseph G Potian; Carmen C Garcia; Kormakur Hognason; Katerina Capková; Scott T Moe; Alan R Jacobson; Kim D Janda; Joseph J McArdle
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

9.  Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain.

Authors:  Hajime Seki; Sabine Pellett; Peter Silhár; G Neil Stowe; Beatriz Blanco; Matthew A Lardy; Eric A Johnson; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2013-12-08       Impact factor: 3.641

10.  Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies.

Authors:  Peter Šilhár; Nicholas R Silvaggi; Sabine Pellett; Kateřina Čapková; Eric A Johnson; Karen N Allen; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2012-12-20       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.